{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-040774","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.023656+00:00","generated_at":"2026-05-16T23:23:52.286477+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rocket Pharma Q3 net loss $50.3M; KRESLADI PDUFA March 2026; Danon trial to resume 1H 2026","bullets":["Q3 net loss $50.3M ($0.45/share), down from $66.7M ($0.71) YoY; R&D expenses $34.1M vs $42.3M.","Cash, equivalents, investments $222.8M; runway expected into Q2 2027.","FDA accepted KRESLADI (marne-cel) BLA resubmission for severe LAD-I; PDUFA target March 28, 2026.","Phase 2 trial of RP-A501 for Danon disease to resume dosing in 1H 2026 after FDA lifted clinical hold.","Appointed Dr. Syed Rizvi as CMO, Christopher Stevens as COO, Sarbani Chaudhuri as Chief Commercial & Medical Affairs Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-040774","json":"https://secwatch.observer/filing/0001140361-25-040774.json","markdown":"https://secwatch.observer/filing/0001140361-25-040774.md","text":"https://secwatch.observer/filing/0001140361-25-040774.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125040774/0001140361-25-040774-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125040774/ef20058531_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:23:52.286477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}